In contrast, DLC1 expression significantly decreased in bladder urothelial carcinoma, breast invasive carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), cholangiocarcinoma (CHOL), kidney chromophobe, kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, prostate adenocarcinoma, rectum adenocarcinoma, and uterine corpus EC (UCEC) tissues compared with normal control tissues. This evidence concerns the gene DLC1 and prostate adenocarcinoma.